The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).

TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...

Let’s cover six scientifically backed methods to address the post-stem cell transplant procedure side effects you may be experiencing.

A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall ...

Graft-versus-host disease (GvHD) is a complication of a bone marrow or stem cell transplant in which cells from a donor attack the tissues of the recipient. GvHD can be classified as being either ...

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

Morgans's healthcare analyst Iain Wilkie describes 2024 as "pretty patchy" for the ASX healthcare sector, which has ...